Informazioni sul prodotto
- 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide-d8
- AP 24534-d8
Applications Ponatinib-d8 is an isotope labelled compound of Ponatinib (P688250). Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. It is a COVID19-related research product.
References Skora, L., et al.: ACS Med. Chem. Lett., PagesAhead of Print (2017); Uchibori, K., et al.: Nat. Commun., 8, 14768 (2017); Perrotti, D., et al.: Curr. Drug Targets, 18, 377 (2017); Santarpia, M., et al.: Trans. Lung Cancer Res., 5, 51 (2016); Halbach, S., et al.: Cell Commun. Signal., 14, 6 (2016)
Proprietà chimiche
Richiesta tecnica su: Ponatinib-d8
Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine
